Animal Pharma

Antimicrobial resistance (AMR): how animal pharmaceuticals are driving the next global public health crisis.

Today, 70% of global antimicrobials are fed to intensively farmed livestock, accelerating the risk of widespread antimicrobial resistance. Our latest research, Feeding Resistance, explores the role of animal pharmaceuticals in driving AMR, and how investors can engage the sector to drive better stewardship.

Contact: Jo Raven, Senior Manager, Engagements

Launch Webinar

On 21 July 2021, we held a special webinar to mark the launch of the report and share the key findings from our research. We were joined by a panel of AMR experts, including:

• Dr Emma Berntman, Engagement Lead, EOS at Federated Hermes
• Professor Will Gaze, University of Exeter Medical School
• David Tsoupros, Senior Research Analyst, AllianceBernstein
• Susannah Savage, Lead AMR Reporter, The Bureau of Investigative Journalism

Feeding Resistance

Summary Report


Members & Non-Members

Read the Executive Summary to find out key information regarding the contribution of animal agriculture to AMR and the current practices of the ten largest publicly listed animal pharma companies.

Full Report (Members)



Access the full report to learn about the contribution of animal agriculture to AMR. The analysis examines current practices of the ten largest publicly listed animal pharma companies and outlines key actions that the sector must take to mitigate the risks of AMR.

Full Report (Non-Members)



Delve into our latest report, Feeding Resistance, which provides a unique sectoral analysis of the animal pharma industry and explores the widespread impact of antibiotic use in the livestock industry. The report is now available to non-members for a one-off payment.


The report, Feeding Resistance, analyses the role of pharmaceutical companies in driving the use of antibiotics in livestock farming systems. We recognise that this sectoral analysis will have broad institutional investor appeal and thus, we have opened distribution to a wider investor audience for a fee. The report is available to Investor Members of the FAIRR Initiative at no cost. Non-members may sign up to the FAIRR network to receive the full benefits of membership, including free access to the report.

The FAIRR Initiative has been fully funded by the Jeremy Coller Foundation since its inception in December 2015.

The FAIRR Initiative is part of the Jeremy Coller Foundation, which is a registered charity (no. 1163970) in England and Wales. All proceeds generated from the sale of the report will be reattributed to funding further research on the risks of antibiotic overuse in the animal agriculture sector.

Reports and other research tools will continue to be available to our Investor Members free of charge. The Executive Summary reports will be available at no cost.

Investor Members can access the report for free once they have logged in to their profile. Institutional Investors that are not yet members of the FAIRR Initiative can purchase the full report here.

The FAIRR Initiative is a free-to-join collaborative institutional investor network that provides expert research, data and practical tools for investors to support investors in mitigating risks and identifying opportunities in the global protein supply chain. Currently, FAIRR Membership is only open to institutional investors. To become an Investor Member of the FAIRR network, please apply here. To learn more about our work and the benefits of membership please contact: [email protected]

Thank You

Thank you for your interest in our report, Feeding Resistance: Antimicrobial Stewardship in the Animal Health Industry. You will shortly receive an email with a link to download the report. If you have not received this within the next few minutes, please check your junk folder.